Xylitol Use for Decolonization of C. Difficile in Patients With IBD
Status:
Not yet recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized placebo controlled study to assess the safety and efficacy of xylitol as
an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 72
patients who meet eligibility criteria will be randomized 1:1 to either the xylitol or
sucralose (placebo) arm. Both arms will receive a dose comprising five capsules BID for four
weeks. Microbiome assessment and C. difficile testing will be performed at baseline, week 4,
8, 26, and 52.